Small- and large-fiber neuropathy after 40 years of type 1 diabetes: Associations with glycem ic control andadvanced protein glycation: The Oslo Study

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3712-3717

  Sveen, Kari Anne ^a,b   Karimé, Bassam ^c   Jørum, Ellen ^c   Mellgren, Svein Ivar ^d   Fagerland, Morten Wang ^a   Monnier, Vincent M ^e   Dahl Jørgensen, Knut ^b,f   Hanssen, Kristian F ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; IMIDAZOLE DERIVATIVE; METHYLGLYOXAL; METHYLGLYOXAL DERIVED HYDROIMIDAZOLONE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMIDAZOLONE; LYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCATION; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAEPIDERMAL NERVE FIBER DENSITY; LARGE FIBER NEUROPATHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; NERVE CONDUCTION; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC EXAMINATION; NEUROPATHY; PAIN THRESHOLD; PROSPECTIVE STUDY; QUANTITATIVE SENSORY THRESHOLD; RISK ASSESSMENT; RISK FACTOR; SMALL FIBER NEUROPATHY; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; GLUCOSE BLOOD LEVEL; NERVE FIBER; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PHYSIOLOGY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMIDAZOLES; LYSINE; MALE; MIDDLE AGED; NERVE FIBERS; PYRUVALDEHYDE; SENSORY THRESHOLDS; YOUNG ADULT;

EID: 84890449389     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0788     Document Type: Article

References (26)

1. Smith AG, Singleton Jr. Impaired glucose tolerance and neuropathy. Neurologist 2008;14:23-29
2. Gandhi RA, Marques JL, Selvarajah D, Emery CJ, Tesfaye S. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care 2010; 33:1585-1590
3. Løseth S, Stålberg E, Jorde R, Mellgren SI. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol 2008;255: 1197-1202
4. Dyck PJ, Davies JL, Clark VM, et al. Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006;29:2282-2288
5. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986;293:1195-1199
6. Amthor KF, Dahl-Jørgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994;37:579-584
7. Larsen JR, Sjoholm H, Hanssen KF, Sandvik L, Berg TJ, Dahl-Jorgensen K. Optimal blood glucose control during 18 years preserves peripheral nerve function in patients with 30 years' duration of type 1 diabetes. Diabetes Care 2003;26:2400-2404
8. Albers JW, Herman WH, Pop-Busui R, et al.; Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090-1096
9. Tesfaye S, Chaturvedi N, Eaton SE, et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341-350
10. Orchard TJ, Forrest KY, Ellis D, Becker DJ. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited. Arch Intern Med 1997;157:1851-1856
11. Duran-Jimenez B, Dobler D, Moffatt S, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009;58:2893-2903
12. Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997;40:1380-1387
13. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18:926-933
14. Dahl-Jørgensen K. Near-normoglycemia and late diabetic complications. The Oslo Study. Acta Endocrinol Suppl (Copenh) 1987;284:1-38
15. Dyck PJ, Albers JW, Andersen H, et al.; on behalf of the Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 21 June 2011 [Epub ahead of print]
16. Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976;39:1071-1075
17. Hilz MJ, Stemper B, Axelrod FB, Kolodny EH, Neundörfer B. Quantitative thermal perception testing in adults. J Clin Neurophysiol 1999;16:462-471
18. Løseth S, Lindal S, Stålberg E,Mellgren SI. Intraepidermal nerve fibre density, quantitative sensory testing and nerve conduction studies in a patient material with symptoms and signs of sensory polyneuropathy. Eur J Neurol 2006;13:105-111
19. Gøransson LG, Mellgren SI, Lindal S, Omdal R. The effect of age and gender on epidermal nerve fiber density. Neurology 2004;62:774-777
20. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jørgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998;21:1997-2002
21. Fan X, Sell DR, Zhang J, et al. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: A comparative analysis. Free Radic Biol Med 2010;49: 847-856
22. Vas PR, Green AQ, Rayman G. Small fibre dysfunction, microvascular complications and glycaemic control in type 1 diabetes: a case-control study. Diabetologia 2012; 55:795-800
23. Monnier VM, Sell DR, Strauch C, et al.; DCCT Research Group. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications 2013;27: 141-149
24. Pop-Busui R, Herman WH, Feldman EL, et al.; DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010;10:276-282
25. Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010;53:1093-1098
26. Szramka M, Harriss L, Ninnio D, et al. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007;117:287-291